1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSTTR Phase II: Multifunctional Lipid Nanoparticle Delivery System for Targeted Delivery of Vascular RNA Therapeutics is sponsored by National Science Foundation (NSF). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
STTR Phase I:Multifunctional Lipid Nanoparticle Delivery System for Targeted Delivery of Vascular RNA Therapeutics KNOXVILLE, TN, 37920-6768 Socially and Economically Disadvantaged: No Congressional District: N/A Total Award Amount: $275,000 Agency Tracking Number: 2309031 Solicitation Topic Code: BM Solicitation Number: NSF 23-515 The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project is that the proposed delivery system will advance many RNA therapeutic solutions to address intimal hyperplasia (IH) and other vascular conditions.
Vascular disease is the most common disease pathology in the US, costing the country’s healthcare system over $437 billion dollars annually. Because vascular interventions have limited long-term success, there is a critical need for effective therapeutics, including to address the condition of IH which, post intervention, can lead to restenosis, or artery narrowing.
By delivering therapeutics safely and efficaciously to specific tissues, the proposed technology will result in improved quality of life and decreased morbidity and, in combination with a Contact Research Organization business model, will contribute to the advancement of a multitude of RNA therapeutics targeting the vascular system and eventually other areas of the body.
Eventually, the platform will contribute to the development and commercialization of a broad range of RNA drugs, creating jobs in science, sales, and manufacturing. This project will lead to improvements in the treatment of a variety of diseases and conditions that currently lack effective therapy, resulting in improved quality of life and decreased morbidity in the broader society.
_x000D_ This Small Business Technology Transfer (STTR) Phase I project seeks to develop a novel multifunctional lipid nanoparticle (LNP) delivery system for tissue-specific targeted delivery of RNA therapeutics to the vascular system. Intimal hyperplasia (IH), a condition triggered by mechanical injury to blood vessels, causes artery thickening in ~ 60% of peripheral vascular disease patients 12 months post-intervention.
IH often results in the need for additional surgical intervention with associated costs and increased patient morbidity and mortality. This project will focus on inhibiting the remodeling pathways that lead to IH via RNA therapeutics delivered directly to the injury site.
The project will develop vascular targeting liposomes designed to exhibit multifunctional potential to target exposed collagen matrices specific to areas of vascular pathology and enhanced targeted vascular uptake/delivery. Phase I will advance the LNP technology by showing that an active therapeutic encapsulated by the system is appropriately delivered and results in a clinically relevant drug concentration.
If successful at delivering bioactive RNA payloads to injured vascular tissues, the technology will reduce the risk of post-intervention complications and reduce the need for revascularization. Ultimately, this novel LNP packaging and delivery system will provide a new tool for advancing a broad range of RNA therapeutics.
_x000D_ This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria. Name: The University of Tennessee, Memphis - The Health Science Center
According to the current listing, eligibility includes: Small Businesses. Confirm the full requirements in the official notice before applying.
STTR Phase II: Multifunctional Lipid Nanoparticle Delivery System for Targeted Delivery of Vascular RNA Therapeutics is funded by National Science Foundation (NSF). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
TCUP lists eight funding tracks and roughly $10.3M a year, but the October 14, 2026 deadline applies to only three of them — CHAI, Pre-TI, and TCUP Partnerships — and each carries a restriction that disqualifies most applicants. Here is the track-by-track math.
Read articleNSF 26-513 makes roughly $100 million available for up to 10 State and Regional AI Infrastructure Hubs at $4M to $12M each over five years. One award per state or multi-state region. One proposal per organization. And NSF is not buying you GPUs — it funds the coordination, the workforce and the faculty training, while the compute has to come from partners you have to already have.
Read articleAs of September 12, NSF had obligated $6.3 billion across 6,200 grants versus $8.1 billion and 8,600 last year. AHRQ has made 61 awards. Judge Allison Burroughs ordered the government to report by September 28 on whether IES will obligate $180 million before it expires. Here is what actually happens to the money on October 1 — and what it means for your FY2027 application.
Read article